3 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Glaukos Corporation, GKOS
Summary: Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
- Last Price: $113.91
- Price Change: $-0.05, -0.04%
- Yearly Gain: 69.13%
- Market Cap: $5.74B
- P/E Ratio: -39.55
Here are 3rd party ratings for GKOS:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 36% (159 out of 248)
What is the sentiment on the street regarding Glaukos Corporation ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in GKOS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on GKOS before you decide to make any investment.
Click here for chart >>
Crinetics Pharmaceuticals, Inc., CRNX
Summary: Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States.
- Last Price: $44.71
- Price Change: $-1.13, -2.47%
- Yearly Gain: 106.32%
- Market Cap: $3.53B
- P/E Ratio: -11.86
Here are 3rd party ratings for CRNX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 34% (85 out of 248)
What is the sentiment on the street regarding Crinetics Pharmaceuticals, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in CRNX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CRNX before you decide to make any investment.
Click here for chart >>
-, ATYR
Summary: aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.
- Last Price: $1.98
- Price Change: $0.12, 6.45%
- Yearly Gain: 14.45%
- Market Cap: $0.00
- P/E Ratio: -
Here are 3rd party ratings for ATYR:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 34% (85 out of 248)
What is the sentiment on the street regarding - ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: -
- Insider Signal: Selling
- Investor Sentiment: -
- Hedge Fund signal: Risk Not Mentioned
If you are interested in ATYR or any stocks within the - sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ATYR before you decide to make any investment.
Click here for chart >>
Thanks for reading!